Mecamylamine clinical pharmacology: Difference between revisions
(Created page with "__NOTOC__ {{Mecamylamine}} {{CMG}}; {{AE}} {{AK}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET...") |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
==CLINICAL PHARMACOLOGY== | |||
Mecamylamine HCl reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a long-lasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. | |||
Pharmacokinetics and Metabolism | |||
Mecamylamine HCl is almost completely absorbed from the gastrointestinal tract, resulting in consistent lowering of blood pressure in most patients with hypertensive cardiovascular disease. Mecamylamine HCl is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine. | |||
Mecamylamine HCl crosses the blood-brain and placental barriers.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6822ce4-e741-4366-b72a-5f5146354f97 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=c6822ce4-e741-4366-b72a-5f5146354f97 | publisher = | date = | accessdate = 10 March 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 14:38, 10 March 2014
| Mecamylamine |
|---|
| Mecamylamine tablet®, Vecamyl® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Patient Counseling Information |
| Labels and Packages |
| Clinical Trials on Mecamylamine |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
CLINICAL PHARMACOLOGY
Mecamylamine HCl reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a long-lasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced.
Pharmacokinetics and Metabolism
Mecamylamine HCl is almost completely absorbed from the gastrointestinal tract, resulting in consistent lowering of blood pressure in most patients with hypertensive cardiovascular disease. Mecamylamine HCl is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine.
Mecamylamine HCl crosses the blood-brain and placental barriers.[1]
References
- ↑ "VECAMYL (MECAMYLAMINE HYDROCHLORIDE) TABLET [MANCHESTER PHARMACEUTICALS]". Retrieved 10 March 2014.